Gemcitabine for metastatic pancreatic cancer patients
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests gemcitabine chemotherapy in people with metastatic pancreatic cancer who cannot take FOLFIRINOX. It aims to see how well gemcitabine works based on a specific tumor marker called GemCore.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with metastatic pancreatic adenocarcinoma (cancer that has spread).
- You cannot receive FOLFIRINOX chemotherapy and your doctor plans to treat you with gemcitabine alone.
- Your tumor sample is available and has enough cancer cells to test for the GemCore marker.
- You have not had chemotherapy for metastatic disease before.
- Your life expectancy is more than 2 months, and you have measurable tumors on scans.
- You are 18 years or older, willing to participate, and covered by health insurance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding Gembrax (a combination that includes gemcitabine and nab-paclitaxel) before standard FOLFIRINOX works better than FOLFIRINOX alone in people with pancreatic cancer that has already spread. It looks at whether this “step-up first” approach improves results and is still tolerable.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests if adding leflunomide (a drug used for arthritis) to standard chemotherapy (gemcitabine) can help people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination works better than gemcitabine alone.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
This trial studies whether adding canagliflozin to standard chemotherapy (gemcitabine) can slow pancreatic cancer that cannot be fully removed by surgery. It may help some people control the cancer for longer and improve how well treatment works.
This trial tests an oral medication called GAS in people with pancreatic cancer that has spread to other parts of the body, who have not yet received any treatment for metastatic disease. The goal is to find the best dose and see how well it works.
Hear when a new Cancer Of Pancreas trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.